 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Feb 22 Calls Today's Calls |
| Call Details | |||
| ev3 Inc. Earnings Conference Call (Q4 2007) Fri, Feb 22, 2008, 8:30 am Eastern
| |||
| About ev3 Inc. (NasdaqGS:EVVV) | |||
| ev3, Inc., a medical device company, focuses on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. It operates in two segments, Cardio Peripheral and Neurovascular. The Cardio Peripheral segment provides peripheral vascular products, which are used to treat vascular disease in legs, kidney, neck, and vascular diseases other than in the brain or the heart. It also offers cardiovascular products, which are used to treat coronary artery disease, atrial fibrillation, and other disorders in heart. This segment’s products portfolio includes stents, embolic protection products, carotid stenting solutions, thrombectomy products, and procedural support products that are used primarily by radiologists, vascular surgeons, and cardiologists. The Neurovascular segment provides products that are used to treat vascular disease and disorders in the brain, including aneurysms and arterial-venous malformations. This segment offers various products, including embolic coils, liquid embolics, neuro stents, microcatheters, occlusion balloon systems, and guidewires used by neuroradiologists and neuro surgeons. The company markets its products in the United States, Europe, and Canada through a direct sales force, and through distributors in certain international markets. ev3, Inc. has a research collaboration with Merck & Co., Inc. for the analysis of atherosclerotic plaque removed from patient arteries with the goal of identifying new biomarkers for atherosclerotic disease progression and new therapies for atherosclerotic disease. The company is headquartered in Plymouth, Minnesota. | |||
More Info: | |||
